[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"juvenile-idiopathic-arthritis-jia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:juvenile-idiopathic-arthritis-jia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,74,100,145,170,195,221,252,280,308,328,354,379,407],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100641335","yoga-for-children-with-juvenile-idiopathic-arthritis-100641335",false,"NCT07661069","YOGA FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS","INVESTIGATING THE EFFECTIVENESS OF TELEREHABILITATION-BASED YOGA EXERCISES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS","JIA","Inclusion Criteria:\n\n* Being between 8 and 12 years of age.\n* Diagnosed with Juvenile Idiopathic Arthritis (JIA) by a pediatric rheumatologist.\n* Having no major changes in pharmacological treatment within the last 3 months.\n* Having reliable internet access and the necessary technological equipment to participate in online video sessions.\n* Voluntary participation in the study.\n* Providing written parental informed consent and child assent.\n\nExclusion Criteria:\n\n* Being in an acute disease flare-up\u002Fattack period.\n* Having undergone orthopedic surgery within the last 6 months.\n* Presence of severe cardiopulmonary or neurological conditions that contraindicate participating in yoga exercises.\n* Cognitive level or impairment that prevents the child from following instructions and verbal cues.\n* Regular participation in another structured exercise or physical rehabilitation program.","ALL","8 Years","12 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"NA","Juvenile Idiopathic Arthritis (JIA) is a chronic autoimmune condition starting before age 16, often leading to fatigue, joint stiffness, and decreased physical activity. While exercise is widely recommended to improve functional capacity in children with JIA, the effectiveness of specialized mind-body exercises like yoga is still being explored. This study aims to investigate the impact of an 8-week, telerehabilitation-based yoga program on children with JIA. Participants will engage in 45-minute individual yoga sessions twice a week via Zoom, led by certified physiotherapists. The sessions will progress in difficulty and focus on breathing techniques, physical postures, and meditation to improve the overall physical and mental well-being of the children.",[28],"Juvenile Idiopathic Arthritis (JIA)","NOT_YET_RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":22},"2026-07-15",{"date":37,"type":22},"2026-10-15",{"name":39,"class":40},"Akdeniz University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100640924","the-bridge-pain-study-100640924","NCT07602595","The BRIDGE Pain Study","Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain","BRIDGE","Inclusion Criteria:\n\n* Diagnosis of rheumatic\u002Fautoimmune disease\u002Fpain condition or surgery prior to age 18; Current age 14 to 26 years; Participant (and parent\u002Flegal guardian of participants \\\u003C 18 yo) can read and write in English; At least 1 year from diagnosis of pain or rheumatic disease; For individuals with MSK surgical history, at least 1 year after initial surgical intervention; For individuals with rheumatic disease, their disease must be considered inactive\n\nExclusion Criteria:\n\n* They have active disease, or Other major medical comorbidities have developed after surgery following MSK surgical intervention.","14 Years","26 Years",{"count":52,"type":22},600,"4 Weeks","OBSERVATIONAL","The purpose of the study is to discover at least two distinct Musculoskeletal pain subtypes. These types are caused by different brain-and-immune system signals that affect how the body feels pain, and they are also shaped by a person's biology, psychology, and social environment.\n\nAim 1. We want to sort adolescents and young adults with long lasting muscle and bone pain into two different groups. To do this, we will look at participants' childhood medical histories, past treatments, when their pain started, the sex they were assigned at birth, what their pain feels like now, tests of how their body senses pain, and immune system markers found in their blood. We think we will find at least two different types of chronic pain groups, plus one group of patients who had a higher risk for pain (because of a rheumatic disease or past surgery) but never developed long term pain.\n\nAim 2. We want to find out if certain patterns of inflammation in the body change how nerve cells react to pain.\n\nAim 3: We want to understand how different biological, psychological, and social factors are connected to the chronic pain groups we identified. We think we will find certain mental, behavioral, and social risks-as well as protective factors-that help explain why some people develop long-lasting pain and others do not. We expect these factors to play different roles in each pain group, including the group that does not develop chronic pain.",[28,57,58,59,60,61,62],"Fibromyalgia","Lupus","Scoliosis","Pectus Excavatum","Chronic Pain","Musculoskeletal Pain","RECRUITING","2026-05-16",{"date":66,"type":33},"2026-05-22",{"date":68,"type":22},"2026-08",{"date":70,"type":22},"2029-08",{"name":72,"class":40},"Children's Hospital Medical Center, Cincinnati",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100635476","phase-3-ole-study-with-filgotinib-in-jia-100635476","NCT07553182","OLE Study With Filgotinib in JIA","Open-label Extension (OLE), Multiple Dose Study to Evaluate Safety, Tolerability, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis (JIA)","OLE JIA","Inclusion Criteria:\n\n* Subject must have completed treatment with filgotinib in at least one parent study and achieved a clinical benefit at the end of the parent protocols\n* Subject and\u002For parent\u002Flegal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee\u002F Institutional Review Board, prior to any protocol evaluations\n* Female or male subject 8 to \\\u003C18 years of age, on the date of signing the informed consent and assent (per local regulation) form\n* Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception\u002Fpreventive exposure measures as described in the clinical study protocol.\n\nExclusion Criteria:\n\n* Development of any condition during the parent study that would preclude safe continuation\n* Pregnancy\n* Active infection that is clinically significant, as per Investigator's judgement\n* Subject with known hypersensitivity to the components of potential study therapy\n* Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements","18 Years",{"count":84,"type":22},80,[86],"PHASE3","This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period\u002Fprolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.",[28],"2026-04-21",{"date":91,"type":33},"2026-04-27",{"date":93,"type":33},"2026-04-20",{"date":95,"type":22},"2027-12",{"name":97,"class":98},"Alfasigma S.p.A.","INDUSTRY",4,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":17,"minAge":19,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":127,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100599701","phase-4-safety-and-immunogenicity-of-the-live-attenuated-tetravalent-butantan-dengue-vaccine-in-autoimmune-rheumatic-diseases-100599701","NCT07087912","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine (Butantan-DV) in Patients With Autoimmune Rheumatic Diseases Living in Dengue-Endemic Areas","BTNDV-ARD","Inclusion Criteria:\n\n* Age between 12 and 59 years\n* Male or female\n* Clinical diagnosis of an autoimmune rheumatic disease (ARD) based on internationally accepted criteria (e.g., rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren's syndrome, vasculitis)\n* Healthy control matched by age and sex\n* ARD patients with clinically stable disease for at least 3 months\n* ARD patients under low-grade immunosuppression or no immunosuppression\n* Acceptable immunosuppressive treatments include:\n\nHydroxychloroquine Sulfasalazine Prednisone ≤ 20 mg\u002Fday Methotrexate ≤ 0.4 mg\u002Fkg\u002Fweek (maximum 20 mg\u002Fweek) Leflunomide 20 mg\u002Fday Azathioprine \\\u003C 3 mg\u002Fkg\u002Fday Combination therapy with low-dose prednisone (≤ 7.5 mg\u002Fday), hydroxychloroquine, or sulfasalazine\n\n* Healthy controls with no history of autoimmune or chronic infectious diseases\n* Healthy controls not taking immunosuppressive medications Willing and able to comply with study procedures and follow-up\n* Female participants of reproductive potential with negative pregnancy test at baseline\n* Female participants of reproductive potential agreeing to use effective contraception for at least 90 days after vaccination\n\nExclusion Criteria:\n\n* Prior receipt of any dengue vaccine\n* Receipt of a live attenuated vaccine within 4 weeks prior to enrollment\n* Receipt of an inactivated vaccine within 2 weeks prior to enrollment\n* Known allergy to any component of the vaccine\n* Febrile illness (≥ 37.8°C) within 72 hours prior to vaccination\n* History of immunodeficiency syndromes\n* History of asplenia\n* History of cancer\n* History of HIV infection\n* History of primary immunodeficiencies\n* Immunosuppression due to organ transplant\n* Chronic uncontrolled comorbidities (e.g., heart failure, renal failure, hepatic insufficiency, diabetes mellitus)\n* Hospitalization or acute illness at screening\n* Receipt of blood transfusion within 3 months prior to enrollment\n* Current pregnancy or breastfeeding\n* Intention to become pregnant within 90 days post-vaccination\n* Participation in another clinical trial within 30 days prior to enrollment",true,"59 Years",{"count":111,"type":22},477,[113],"PHASE4","The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune rheumatic diseases (ARDs) who are clinically stable and under low-grade or no immunosuppression, as well as in healthy volunteers matched by sex and age.\n\nThe main questions it aims to answer are:\n\nDoes the vaccine induce adequate seroconversion in patients with ARDs compared to healthy controls? What is the frequency and intensity of common adverse events after vaccination in ARDs patients? Does physical activity levels and nutritional status influence vaccine-induced immune response in patients with ARDs?\n\nResearchers will compare patients with ARDs to healthy controls to evaluate if the vaccine elicits similar immune responses and safety profiles.\n\nAll participants will:\n\n* receive a single 0.5 mL dose of the Butantan-DV vaccine via subcutaneous injection;\n* undergo blood sample collection before and after vaccination (baseline, Day 42, and Day 400) to assess antibody and cellular responses;\n* attend follow-up visits on Days 7, 14, and 42 for safety monitoring and laboratory tests;\n* report any symptoms or adverse events using a standardized diary for 42 days;\n* be followed for up to one year for long-term safety and immunogenicity assessments.\n* wear a device for 14 consecutive days to assess current and habitual physical activity levels.\n* answer three non-consecutive 24-hour dietary recalls, including at least one weekend day to assess nutritional status.\n* collect blood samples one-year after vaccination to access immunogenicity and cellular response.\n\nResearcher will also perform subgroups analysis in:\n\nA viremia subgroup (50 patients and 50 healthy controls) will provide additional samples on Days 1, 7, 14, 28, 42, and-if viremia is detected-Day 68, to evaluate post-vaccination viremia and its duration.\n\nAn immunogenicity subgroup (\\~20% of participants, n=96) will undergo cellular immune response testing via flow cytometry to evaluate T-cell responses.",[116,28,117,118,119,120,121,122,123,124,125,126],"Rheumatoid Arthritis (RA)","Systemic Lupus Erythematosus (SLE)","Juvenile Systemic Lupus Erythematosus","Systemic Sclerosis (SSc)","Idiopathic Inflammatory Myopathies (IIMs)","Axial Spondyloarthritis","Psoriatic Arthritis (PsA)","Granulomatosis With Polyangiitis","Microscopic Polyangiitis","Antiphospholipid Syndrome","Takayasu Arteritis",[128,129,130,131,132,133,134],"Tetravalent Vaccine","Butantan-Dengue Vaccine","Autoimmune Rheumatic Diseases","Rheumatology","Pediatric Rheumatology","Infectious Disease Prevention","Vaccine","2026-04-14",{"date":137,"type":33},"2026-04-15",{"date":139,"type":22},"2026-03-16",{"date":141,"type":22},"2028-12-30",{"name":143,"class":40},"University of Sao Paulo General Hospital",2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":82,"enrollmentInfo":152,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100609236","tofacitinib-in-juvenile-idiopathic-arthritis-100609236","NCT07211932","Tofacitinib in Juvenile Idiopathic Arthritis","Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.","Inclusion criteria:\n\nDiagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.\n\nDocumentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.\n\nAge under 18 years at the time of the treatment indication with tofacitinib.\n\nExclusion criteria:\n\nParticipants diagnosed with any of the following conditions:\n\nReactive arthritis\n\nArthritis associated with inflammatory bowel disease\n\nArthritis associated with another autoimmune disease",{"count":153,"type":22},58,"This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.",[28],[157,158,159],"Arthritis, Juvenile","tofacitinib [Supplementary Concept]","Janus Kinase Inhibitors","2025-11-21",{"date":162,"type":33},"2025-11-26",{"date":164,"type":22},"2025-12",{"date":166,"type":22},"2026-12",{"name":168,"class":40},"Consorci Sanitari de l'Alt Penedès i Garraf",3,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":73},"100610989","structured-vs-exergaming-based-core-stabilization-in-children-with-juvenile-idiopathic-arthritis-100610989","NCT07234747","Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis","Comparison of the Effects of Structured Core Stabilization Exercise Training and Exergaming-Based Core Stabilization Training in Children With Juvenile Idiopathic Arthritis","Inclusion Criteria:\n\n* Being between the ages of 8 and 13\n* Having been diagnosed with JIA at least 6 months prior\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Having a balance problem due to vestibular or neurological conditions\n* Having undergone surgery in the last 6 months that may interfere with exercise participation\n* Inability to comply with the exercise program",{"count":178,"type":22},30,[25],"Juvenile Idiopathic Arthritis (JIA) is the most common inflammatory, autoimmune, and chronic rheumatic disease of childhood (1). In individuals diagnosed with JIA, increased inflammation leads to joint swelling, tenderness, restricted range of motion, and pain (2,3). Over time, these symptoms may result in impaired movement and proprioception, reduced muscle strength, and gait abnormalities (2,3).\n\nAlthough ongoing medical treatment has been demonstrated to be highly effective in suppressing inflammation in children with rheumatic diseases, persistent pain despite treatment may limit mobility and contribute to the development of kinesiophobia. This condition may lead to the adoption of a sedentary lifestyle (4). A sedentary lifestyle may subsequently result in reduced functional capacity and physical fitness, increased risk of social isolation, and a decline in overall quality of life (5).\n\nAccording to the literature, physical activity in children with rheumatologic diseases has been shown to reduce inflammation, increase muscle strength, improve functional capacity and mental health, reduce fatigue, and enhance quality of life (6,7). Non-pharmacological therapeutic exercise interventions have been found effective in alleviating chronic disease-related symptoms in children and in preventing secondary complications (8). The effectiveness of exercise therapy in children with JIA has been demonstrated in several studies, with commonly used programs including balance, proprioception, resistance, and range of motion exercises (9). However, only a limited number of studies have incorporated core-focused stabilization exercises into treatment protocols for children with JIA.\n\nAlthough Core Stabilization Training (CST) initially gained popularity among athletes, it has since been integrated into rehabilitation programs and applied across various patient populations (10,11). CST is defined as the ability to control muscle activation in the lumbo-pelvic region, which is necessary for spinal stabilization and for transferring core strength from the trunk to the extremities. CST has been shown to positively affect standing, sitting, balance, postural stability, and gait (12).\n\nA review of the literature confirms that Core Stabilization Training (CST) has beneficial effects on quality of life, pain, cardiorespiratory fitness, and functional ability (13). In studies involving children with Juvenile Idiopathic Arthritis (JIA), CST interventions were typically applied over a period of 12 weeks, with 2-3 sessions per week. The outcomes observed in this population were consistent with findings in the broader literature, supporting the effectiveness of CST in children with JIA (14).\n\nExergaming has emerged as an innovative approach to integrating physical activity into daily life (15). In the literature, exercise programs utilizing exergaming across various populations are frequently encountered. These studies have demonstrated multiple benefits of exergaming, including promoting physical activity, reducing perceived exertion, adapting physical activity to individual needs, and improving physical fitness (16). In children diagnosed with JIA, exergaming programs have shown improvements in physical performance and exercise skills, as well as significantly enhanced patient satisfaction (17). However, to date, no study has been identified in the literature that investigates the use of exergaming-based core stabilization training specifically in children with JIA.\n\nThe aim of the study is to compare the effects of an exergaming-based core stabilization training program and a structured core stabilization training program on physical fitness and functional capacity in children with Juvenile Idiopathic Arthritis (JIA). The study is designed as a randomized controlled trial. Children diagnosed with JIA will be included and randomly assigned to one of two groups. One group will receive structured core stabilization training, while the other will receive core stabilization training through exergaming. Both interventions will be administered over a 12-week period, with sessions held twice per week, each lasting 45 minutes.\n\nTo the best of available knowledge, this will be the first study to investigate the effectiveness of a core stabilization exercise program using exergaming in this population. This study is expected to contribute valuable insights to the literature on improving physical fitness and functional capacity in children with Juvenile Idiopathic Arthritis (JIA). Furthermore, it will provide the first clinical and scientific evidence regarding the innovative use of exergaming as a method for delivering core stabilization exercises.",[28],[183,184,185],"core stabilization","juvenile idiopathic arthritis","exergaming","2025-11-14",{"date":188,"type":33},"2025-11-18",{"date":190,"type":33},"2025-04-10",{"date":192,"type":22},"2026-01-10",{"name":194,"class":40},"Istanbul University - Cerrahpasa",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":82,"enrollmentInfo":203,"targetDuration":205,"studyType":54,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":73},"100607222","investigation-of-catastrophizing-of-pain-reported-by-parents-in-jia-patients-100607222","NCT07185750","Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients","Investigation of Biopsychosocial Characteristics According to Catastrophizing of Pain Reported by Parents in Patients Diagnosed With JIA","Inclusion Criteria:\n\n* Between 7-18 years of age\n* Diagnosed with JIA\n* Individuals who volunteer to participate in the study will be included.\n\nExclusion Criteria:\n\n* Having advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease, or malignancies\n* Having undergone major orthopedic surgery\n* Not volunteering to participate in the study","7 Years",{"count":204,"type":22},50,"5 Days","Juvenile idiopathic arthritis (JIA) is the primary rheumatic disease reported to affect the pediatric population. Research suggests that parents' thoughts and feelings about their child's pain, specifically with JIA diagnosis, may influence treatment compliance. Considering that this situation may also affect children's adherence to treatment, the identification and management of parents' catastrophizing of pain is emphasized as important in improving treatment outcomes. This study aimed to examine the biopsychosocial characteristics of parents of children diagnosed with JIA according to their reported catastrophizing of pain.",[28,208],"Childhood Rheumatic Diseases",[210,211],"Pain catastrophizing","chronic pain","2025-09-18",{"date":214,"type":33},"2025-09-22",{"date":216,"type":33},"2025-08-04",{"date":218,"type":22},"2027-08-04",{"name":220,"class":40},"Hacettepe University",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":73},"100480312","angiogenic-biomarkers-in-juvenile-idiopathic-arthritis-100480312","NCT05534347","Angiogenic Biomarkers in Juvenile Idiopathic Arthritis","Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis","MAJIC","Inclusion Criteria:\n\n* Greater than or equal to 16 years-old\n* Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital\n* No-opposition to the research\n* Patient with health insurance\n* Mastery of the French language\n\nExclusion Criteria:\n\n* Patient under curatorship or guardianship\n* Patient receiving french state medical aid","16 Years",{"count":231,"type":22},300,"The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and\u002For therapeutic escalation.",[28],[235,236,237,238,239,240,241,242],"Juvenile idiopathic arthritis (JIA)","JIA patients in transition towards adult ward","Prognosis of JIA","Severity and structural damage in JIA","Angiogenic and inflammatory biomarkers","Semaphorin (SEMA4A), CCN1","Serum fluid","Synovial fluid","2025-09-05",{"date":245,"type":33},"2025-09-12",{"date":247,"type":33},"2023-03-13",{"date":249,"type":22},"2030-03",{"name":251,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":108,"sex":17,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":73},"100597996","quantification--classification-of-inflammatory-cells-in-uveitis-using-oct-100597996","NCT07065747","Quantification & Classification of Inflammatory Cells in Uveitis Using OCT","Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis\u002FHLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.\n2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).\n3. Healthy\u002FControl Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.\n\nExclusion Criteria:\n\n1. Inability to give informed consent.\n2. Inability to maintain stable fixation for OCT imaging.\n3. Inability to commit to required visits to complete the study.\n4. Pregnancy and breastfeeding.","5 Years","85 Years",{"count":262,"type":22},125,"The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.",[265,266,267,268,28,269,270,271],"Anterior Uveitis (AU)","Birdshot Chorioretinitis","Behcet Disease","Herpes Simplex Virus","Spondyloarthritis (SA)","Sarcoidosis","Posterior Vitreous Detachment","2025-07-14",{"date":274,"type":33},"2025-07-17",{"date":276,"type":33},"2024-09-01",{"date":166,"type":22},{"name":279,"class":40},"Oregon Health and Science University",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":82,"enrollmentInfo":287,"targetDuration":289,"studyType":54,"phases":4,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":5},"100304639","capri-national-juvenile-idiopathic-arthritis-registry-100304639","NCT03245801","CAPRI National Juvenile Idiopathic Arthritis Registry","The Canadian Alliance of Pediatric Rheumatology Investigators National Juvenile Idiopathic Arthritis Registry","Inclusion Criteria:\n\n1. All patients newly diagnosed with JIA within the last 3 months\n2. All patients who participated in the original ReACCh-Out study\n3. LEAP study patients from 'newly diagnosed' and 'ReACCh-Out' cohorts who have completed their two year follow up in LEAP\n\nExclusion Criteria:\n\n1. Patients with an unconfirmed JIA diagnosis\n2. Patients diagnosed with JIA more than 3 months prior to the clinic visit, who were not followed in LEAP and \u002For ReACCh-Out studies.\n3. If the family as a whole is unable to answer questionnaires in English or French",{"count":288,"type":22},1238,"10 Years","Juvenile Idiopathic Arthritis (JIA) is a disorder of unknown cause characterized by chronic inflammation of the joints and other organs. It affects about 1 in a 1000 Canadian children and if untreated it can produce lifelong disability. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) includes most pediatric rheumatologists in Canada. They have successfully collaborated for the past 20 years producing groundbreaking research on the modern course and outcomes of JIA. The CAPRI JIA Registry is an ongoing universal registry of Canadian children with JIA that collects longitudinal data on disease course, outcomes and adverse events to inform healthcare decisions and to gain new insights into the disease and its treatment.",[28],[293,294,295,296,297,298],"Juvenile idiopathic arthritis","Canada","Registry","Clinical outcomes","Adverse events","CAPRI","2025-06-24",{"date":301,"type":33},"2025-06-25",{"date":303,"type":33},"2017-02-01",{"date":305,"type":22},"2026-02-01",{"name":307,"class":40},"University of British Columbia",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":314,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":144},"100578090","reliability-and-validity-of-the-glittre-activities-of-daily-living-test-in-children-and-adolescents-with-juvenile-idiopathic-arthritis-100578090","NCT06806774","Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopathic Arthritis","Inclusion Criteria:\n\n* Being diagnosed with Juvenile Idiopathic Arthritis (JIA) according to The International League of Associations for Rheumatology (ILAR) classification\n* Being between the ages of 8-18\n* Volunteering to participate in research\n\nExclusion Criteria:\n\n* Advanced heart\u002Flung\u002Fliver\u002Fkidney disease, neurological disease and malignancies\n* Having undergone major orthopedic surgery\n* Not volunteering to participate in the study",{"count":84,"type":22},"Juvenile Idiopathic Arthritis (JIA) is children's most common inflammatory rheumatic disease. The International League of Associations for Rheumatology (ILAR) defines it as a chronic arthritis condition that begins before the age of 16 lasts for six weeks or more, and has an unknown cause. Despite the gains made in the management of the disease of individuals with JIA with modern medical treatment methods, the physical and psychosocial problems caused by chronic inflammation negatively affect the daily living activities of individuals with JIA. On the other hand, in the JIA Core Set created by Outcome Measures in Rheumatology (OMERACT) in 2018, activities of daily living were included as a \"mandatory area that should be evaluated in all studies.\" Therefore, to ensure that individuals with JIA reach a state of complete well-being, multi-interdisciplinary health professionals are expected to address the activities of daily living, identify the factors that limit these activities, and create intervention plans for the factors to be determined. The literature shows that the daily living activities of patients with JIA are addressed with a limited number of subjective measurement tools. However, these methods have disadvantages due to their subjectivity. In this case, objective measurement methods are needed to quantify the physical performance of patients with JIA in terms of their daily living activities. The Glittre Activities of Daily Living Test, initially developed by selecting activities similar to daily living activities to evaluate functional capacity in pulmonary diseases, has the potential to address this gap. Since the activities in the test require using both the lower and upper extremities, it has the advantage of reflecting functional capacity and providing information about performance in daily life activities. Although it has potential, the Glittre Activities of Daily Living Test needs appropriate psychometric properties for clinical settings and research for JIA patients. To our knowledge, no studies have been conducted in the current literature on the validity and reliability of the Glittre Activities of Daily Living Test in JIA patients. Therefore, this study aimed to evaluate the test-retest reliability, construct validity, and minimum detectable change of the Glittre Activities of Daily Living Test in assessing activities of daily living in children and adolescents with JIA.",[28],[318,319,320,184,321],"activities of daily living","reliability","validity","functional capacity",{"date":323,"type":33},"2025-04-15",{"date":190,"type":33},{"date":326,"type":22},"2026-10-31",{"name":220,"class":40},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":336,"maxAge":82,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":73},"100583306","evaluation-of-the-efficacy-and-tolerability-of-an-exclusion-diet-in-patients-with-juvenile-idiopathic-arthritis-100583306","NCT06874608","Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis","Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis: Interventional, Exploratory Single-center, Randomized, Controlled, Open-label, add-on Study","JIA-ED","Inclusion Criteria:\n\n* Confirmed diagnosis of juvenile idiopathic arthritis (JIA) in the forms of enthesitis-related arthritis and oligoarticular forms according to the ILAR 2001 criteria (https:\u002F\u002Fmedicalcriteria.com\u002Fweb\u002Freujia\u002F);\n* Age between 6 and 18 years (not yet 18);\n* Active disease of mild to moderate severity, assessed through the Juvenile - Arthritis Disease Activity Score (JADAS10) tool (Trincianti C. et al., American College Rheumatology, 2021);\n* For study groups 2 and 3: failure of ongoing pharmacological therapy at the time of screening, defined as a failure to achieve at least a 20% reduction in JADAS10 values after 3 months of initiating DMARD therapy or biologic medication, or if the disease is inactive on such therapy, a 20% increase in those values;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients requiring systemic immunosuppressive therapy for active uveitis;\n* Patients undergoing therapy with systemic corticosteroids (defined as prednisone equivalent \\>0.5 mg\u002Fkg for \\>7 days) or intra-articular corticosteroids in the 3 months prior to enrollment;\n* Patients with fecal calprotectin values \\> 250 mcg\u002Fg at the time of screening;\n* Use of antibiotics in the month prior to enrollment.","6 Years",{"count":338,"type":22},20,[25],"The JIA-ED study is a pilot project. Based on experience in another inflammatory disease, a 4-week period was extrapolated as sufficient to assess the effectiveness of the experimental intervention. This observation is supported by literature data showing that, halfway through phase I of the CDED (Crohn Diseasse Exclusion Diet), it is already possible to identify a subset of patients with Crohn's disease who are responsive to the dietary treatment and who also have a higher likelihood of achieving clinical remission by the end of the first phase of the diet itself.",[28],[15,343,344],"CDED","Dietary therapy","2025-03-12",{"date":347,"type":33},"2025-03-13",{"date":349,"type":33},"2024-12-12",{"date":351,"type":22},"2025-11-15",{"name":353,"class":40},"Meyer Children's Hospital IRCCS",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":108,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":99},"100582402","study-on-eating-habits-and-association-with-omic-profiles-in-families-with-a-subject-affected-by-a-chronic-immune-mediated-inflammatory-pathology-observational-multicenter-study-100582402","NCT06862843","Study on Eating Habits and Association with \"omic\" Profiles in Families with a Subject Affected by a Chronic Immune-mediated Inflammatory Pathology. Observational Multicenter Study.","DIETA-MICIREUM","Inclusion Criteria:\n\nFor families with at least one child\u002Fadult affected by IBD\u002FJIA:\n\n* Father and mother with children aged between 0-18 years, in good health.\n* At least one adult or one child affected by IBD, or a child affected by JIA, regardless of ongoing therapy and without distinction of disease severity or activity.\n\nFor healthy families:\n\n\\- Father and mother with children aged between 0-18 years, in good health and not affected by chronic inflammatory bowel diseases or chronic autoimmune inflammatory diseases in general.\n\nExclusion Criteria:\n\nFor subjects affected by IBD:\n\n* Monogenic disease\n* Children with an ileostomy or who have undergone a colectomy\n\nFor subjects affected by JIA:\n\n\\- No exclusion criteria\n\nFor healthy subjects:\n\n\\- Any chronic inflammatory bowel disease, autoimmune disease, or ongoing infectious diseases.",{"count":362,"type":22},90,"The proposed study is part of a PNRR 2022 project (call \"Non-Communicable Chronic Diseases (NCDs) with high impact on healthcare and social assistance systems,\" currently awaiting funding response) and represents the continuation of an observational clinical study named TRANSMIC, approved by the pediatric ethics committee of the Tuscany region. TRANSMIC was an integral part of a European research project within the joint programming initiative (JPI), under the HDHL-INTIMIC theme: \"A Healthy Diet for a Healthy Life,\" aimed at understanding the cause-effect relationships between diet, gut microbiome, and human health.\n\nUnderstanding the role of diet in inflammatory bowel diseases (IBD) and exploring its role in autoimmune inflammatory conditions with joint manifestations, such as JIA, provides additional insights into the development, progression, and management of these conditions, opening new horizons for the use of dietary treatments in preventing these inflammatory conditions.",[28,365,366],"Crohn Disease (CD)","Ulcerative Colitis (UC)",[15,368,369,370,371],"Dietary habits","CD","UC","IBD","2025-03-03",{"date":374,"type":33},"2025-03-06",{"date":376,"type":33},"2024-02-07",{"date":351,"type":22},{"name":353,"class":40},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":108,"sex":17,"minAge":336,"maxAge":82,"enrollmentInfo":386,"targetDuration":388,"studyType":54,"phases":4,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100570317","gait-profile-and-variables-in-pediatric-rheumatic-disease-using-a-smart-insole-system-100570317","NCT06705673","Gait Profile and Variables in Pediatric Rheumatic Disease Using a Smart Insole System","Investigation of Gait Profile and Variables of Children and Adolescents with Pediatric Rheumatic Disease Using a Smart Insole System","Inclusion Criteria:\n\nChildren and adolescents with pediatric rheumatic disease:\n\n* Aged 6-18 years\n* Diagnosed with JIA or FMF at least 6 months ago at the Istanbul Medical Faculty Pediatric Rheumatology Clinic\n\nHealthy children and adolescents:\n\n* Aged 6-18 years\n* Willing to participate in the study\n\nExclusion Criteria:\n\nExclusion criteria for children and adolescents with pediatric rheumatic disease:\n\n* History of trauma or surgery affecting the musculoskeletal system in the last 6 months\n* Presence of a chronic disease other than JIA or FMF\n* Acute pain for any reason\n* Visual or hearing problems\n* Cognitive impairment that prevents understanding of given instructions\n\nExclusion criteria for healthy children and adolescents:\n\n* History of trauma or surgery affecting the musculoskeletal system in the last 6 months\n* Hearing or visual problems\n* Acute pain for any reason",{"count":387,"type":22},60,"1 Day","In pediatric rheumatic diseases, joint swelling, effusion, tenderness, and painful restriction of joint movement, particularly in weight-bearing joints, frequently alter walking function. These changes affect temporal and spatial parameters of gait, as well as kinematic and kinetic characteristics, leading to functional limitations. Comprehensive physical assessments in patients may not always predict changes in gait parameters. Therefore, incorporating objective methods related to gait and balance into physical evaluations is essential for functional insights and clinical decision-making, aiming to prevent adaptive mechanisms that could negatively affect gait function in the long term. In this context, smart insoles have emerged as a new tool for gait analysis, offering an alternative to high-cost, lab-based equipment. The Digitsole Pro® system can measure gait profile and variables in real-life conditions. A review of the literature reveals no studies utilizing smart insole-based gait assessments in pediatric rheumatic patients. The aim of our study is to investigate the gait profile and variables of children and adolescents with pediatric rheumatic disease using the next-generation Digitsole Pro® smart insole system, and to compare the results with those of healthy peers.",[28,391,392],"Familial Mediterranean Fever (FMF )","Healthy Controls",[394,395,396,397,398],"Juvenile Idıopathic Arthritis","Familial Mediterranean Fever","Gait profile","Smart Insole System","Gait analysis","2024-11-25",{"date":401,"type":33},"2024-11-26",{"date":403,"type":22},"2024-12-02",{"date":405,"type":22},"2025-02-03",{"name":194,"class":40},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":415,"maxAge":82,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":73},"100563651","phase-4-toward-personalized-medicine-to-guide-drug-withdrawal-in-children-with-juvenile-idiopathic-arthritis-in-clinical-remission-100563651","NCT06618937","Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission","Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission: a Randomized Clinical Trial Comparing Early Versus Late Drug Withdrawal Combining Imaging and Multi-Omics","Re-JIA","Inclusion Criteria:\n\n* \\- Children with a diagnosis of JIA according to the ILAR classification criteria\n* JIA patients who satisfy criteria for inactive disease for a minimum of 6 continuous months while still taking medication.\n* Patients who have been treated with cs\u002Fb\u002Fbs\u002Fts DMARDs according to the label indication\n* Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and\u002For patients, as appropriate\n* Duly executed, written, informed consent obtained from the patient's parents\u002Flegal guardian\n* Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial. If sexually active, they must have no intention of conceiving while on treatment with antirheumatic drugs.\n\nExclusion Criteria:\n\n* \\- Patients with systemic JIA according to ILAR criteria\n* Patients with undifferentiated arthritis according to ILAR criteria\n* Patients with severe disease-related ocular damage and who need systemic treatment for uveitis\n* Patients who received glucocorticoid treatment 3 months prior to baseline visit\n* Patients who had previously unsuccessfully attempted tapering cs\u002Fb\u002Fbs\u002FtsDMARDs\n* Patients with severe damage as per caring physician measured\n* Prior or current history of other significant concomitant illness(es) that, according to the Investigator's judgment, would adversely affect the patient's participation in the study\n* Any other medical condition or laboratory examination which in the opinion of the caring physician should exclude the patient from participation to the study","2 Years",{"count":417,"type":22},166,[113],"Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly. Currently, no guidelines exist for withdrawing drugs in JIA patients with clinical inactive disease (CID). Relapses following the withdrawal of antirheumatic drugs are common. To establish an optimal timeline for treatment discontinuation is a major unmet need in pediatric rheumatology.\n\nIt is hypothesized that biomarkers-guided early withdrawal of antirheumatic drugs in patients achieving clinical, imaging and biological remission is safe and more effective compared to the standard practice of maintenance of stable treatment over 12 months.",[28],[15,422,423,424],"imaging","omics","withdrawal","2024-09-27",{"date":427,"type":33},"2024-10-01",{"date":429,"type":22},"2025-01-01",{"date":431,"type":22},"2029-01-01",{"name":433,"class":40},"Istituto Giannina Gaslini"]